3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Lymphoma, Large B-Cell, Diffuse
23
Burkitt Lymphoma
14
Sarcoma
13
Neoplasms
11
Lymphoma, Follicular
11
Lymphoma
10
Hodgkin Disease
9
Breast Neoplasms
9
Triple Negative Breast Neoplasms
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Lymphoma, Non-Hodgkin
8
Endometrial Neoplasms
8
Ovarian Neoplasms
7
Lymphoma, B-Cell
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
5
Wilms Tumor
4
Recurrence
4
Osteosarcoma
4
Neoplasm Metastasis
4
Liposarcoma
4
Fallopian Tube Neoplasms
4
Sarcoma, Ewing
3
Neuroblastoma
3
Lymphoproliferative Disorders
3
Lymphoma, T-Cell
3
Lymphoma, Mantle-Cell
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia, Biphenotypic, Acute
3
Leiomyosarcoma
3
Interventions
pembrolizumab
3
lenvatinib
2
Specimen Handling
2
Nivolumab
2
Cisplatin
2
trastuzumab deruxtecan
1
tivozanib
1
liposomal doxorubicin
1
entinostat
1
dostarlimab
1
bintrafusp alfa protein, human
1
atezolizumab
1
Therapeutic Touch
1
Surveys and Questionnaires
1
Radiotherapy
1
Radiation
1
Platinum
1
Paclitaxel
1
Nelfinavir
1
Magnetic Resonance Spectroscopy
1
Ipilimumab
1
Gemcitabine
1
Doxorubicin
1
Dehydroepiandrosterone
1
CTLA-4 Antigen
1
Bupropion
1
Blood Specimen Collection
1
Bevacizumab
1
Axitinib
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Vulvar Neoplasms
×
Doxorubicin
×
90 days
×
Clear all
NCT06023862
2026-05-06
DOVE
Yonsei University
Phase 2
Recruiting
198 enrolled